Search

Your search keyword '"Hadrien Claus-Desbonnet"' showing total 2 results
Start Over Author "Hadrien Claus-Desbonnet"
2 results on '"Hadrien Claus-Desbonnet"'

1. Polysaccharides and Their Derivatives as Potential Antiviral Molecules

Author

Hadrien Claus-Desbonnet, Elsa Nikly, Vanya Nalbantova, Diana Karcheva-Bahchevanska, Stanislava Ivanova, Guillaume Pierre, Niko Benbassat, Plamen Katsarov, Philippe Michaud, Paolina Lukova, and Cédric Delattre

Subjects
polysaccharides, antiviral activities, virus and coronavirus, severe acute respiratory syndrome, SARS-CoV, replication inhibition, Microbiology, QR1-502
Abstract

In the current context of the COVID-19 pandemic, it appears that our scientific resources and the medical community are not sufficiently developed to combat rapid viral spread all over the world. A number of viruses causing epidemics have already disseminated across the world in the last few years, such as the dengue or chinkungunya virus, the Ebola virus, and other coronavirus families such as Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV). The outbreaks of these infectious diseases have demonstrated the difficulty of treating an epidemic before the creation of vaccine. Different antiviral drugs already exist. However, several of them cause side effects or have lost their efficiency because of virus mutations. It is essential to develop new antiviral strategies, but ones that rely on more natural compounds to decrease the secondary effects. Polysaccharides, which have come to be known in recent years for their medicinal properties, including antiviral activities, are an excellent alternative. They are essential for the metabolism of plants, microorganisms, and animals, and are directly extractible. Polysaccharides have attracted more and more attention due to their therapeutic properties, low toxicity, and availability, and seem to be attractive candidates as antiviral drugs of tomorrow.

Published
2022
Full Text
View/download PDF

2. Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors

Author

Evemie Dubé, Clémence Merlen, Jean St-Louis, Georges-Etienne Rivard, Arnaud Bonnefoy, and Hadrien Claus-Desbonnet

Subjects
Factor VIII, biology, Plasma samples, business.industry, Autoantibody, Quebec, Hematology, Disease, Hemophilia A, Phenotype, Immunoglobulin G, Cohort, Immunology, biology.protein, Acquired hemophilia, Medicine, Humans, In patient, Antibody, business, Autoantibodies
Abstract

Background Acquired haemophilia A (AHA) is a potentially life-threatening bleeding disorder caused by factor VIII (FVIII) autoantibodies, involving various immunoglobulin (Ig) isotypes and IgG subclasses. Objectives We analyzed the profile of Ig against FVIII in patients with AHA to identify Ig patterns predictive of bleeding phenotype and outcomes. Patients/methods Ig detection and titration were determined by enzyme-linked immunosorbent assay (ELISA) at disease presentation in a cohort of 66 subjects from the Quebec Reference Centre for Inhibitors registry. Results Most of plasma samples analyzed (97%) contained multiple anti-FVIII Ig isotypes and IgG subclasses, IgG(1,2,3,4) (24.2%), [IgG(1,2,3,4),IgA] (16.7%) and IgG(2.4) (13.6%) being the most prevalent combinations of Ig detected. AHA patients who presented with IgA antibodies were more likely to have an associated auto-immune disease (p=0.049). The presence of IgG4-was associated with bleeding symptoms at presentation (p=0.002). IgG1-positive patients were more likely to require transfusions with red packed cell (p=0.014) whereas IgM detection was associated with a higher probability of death linked to AHA (p=0.011). Conclusion The Ig pattern of AHA patients at diagnosis is widely heterogeneous and is at least partially associated with some underlying conditions. Our data supports the differential predictive significance for IgG1, IgG4 and IgM on bleeding severity and suggests that the early determination of Ig profile may help to identify AHA patients at higher risk of poorer outcomes.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results